Drug Interactions between dutasteride / tamsulosin and repotrectinib
This report displays the potential drug interactions for the following 2 drugs:
- dutasteride/tamsulosin
- repotrectinib
Interactions between your drugs
tamsulosin repotrectinib
Applies to: dutasteride / tamsulosin and repotrectinib
MONITOR: Coadministration with repotrectinib, a moderate CYP450 3A4 inducer, may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is increased clearance due to induction of CYP450 3A4 activity by repotrectinib. When midazolam, a probe substrate for CYP450 3A4, was administered following treatment with repotrectinib (160 mg once daily for 14 days followed by 160 mg twice daily for 7 days), midazolam systemic exposure (AUC) and peak plasma concentration (Cmax) reduced by 69% and 48%, respectively.
MANAGEMENT: Caution is advised when repotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever repotrectinib is added to or withdrawn from therapy. Avoid concomitant use with repotrectinib where minimal decreases in concentration of the CYP450 3A4 substrate may lead to serious therapeutic failure. If coadministration is required, the CYP450 3A4 substrate dosage should be increased in accordance with approved product labeling.
References (1)
- (2023) "Product Information. Augtyro (repotrectinib)." Bristol-Myers Squibb
dutasteride repotrectinib
Applies to: dutasteride / tamsulosin and repotrectinib
MONITOR: Coadministration with repotrectinib, a moderate CYP450 3A4 inducer, may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is increased clearance due to induction of CYP450 3A4 activity by repotrectinib. When midazolam, a probe substrate for CYP450 3A4, was administered following treatment with repotrectinib (160 mg once daily for 14 days followed by 160 mg twice daily for 7 days), midazolam systemic exposure (AUC) and peak plasma concentration (Cmax) reduced by 69% and 48%, respectively.
MANAGEMENT: Caution is advised when repotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever repotrectinib is added to or withdrawn from therapy. Avoid concomitant use with repotrectinib where minimal decreases in concentration of the CYP450 3A4 substrate may lead to serious therapeutic failure. If coadministration is required, the CYP450 3A4 substrate dosage should be increased in accordance with approved product labeling.
References (1)
- (2023) "Product Information. Augtyro (repotrectinib)." Bristol-Myers Squibb
Drug and food interactions
repotrectinib food
Applies to: repotrectinib
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations and adverse effects of repotrectinib. According to prescribing information, repotrectinib is primarily metabolized by CYP450 3A4, and is also a substrate of P-gp in vitro. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with repotrectinib and grapefruit juice but has been reported for other CYP450 3A4 inhibitors. Drug interaction studies have shown that the administration of repotrectinib with itraconazole, a potent CYP450 3A4 and P-gp inhibitor, increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of repotrectinib by 1.7-fold and 5.9-fold, respectively. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to repotrectinib may increase the risk of adverse reactions such as dizziness, fatigue, cognitive disorders, ataxia, dysgeusia, peripheral neuropathy, muscular weakness, and dyspnea as well as more serious adverse effects such as interstitial lung disease/pneumonitis, liver transaminase elevations, myalgia with creatinine phosphokinase (CPK) elevation, hyperuricemia, and skeletal fractures.
MANAGEMENT: The manufacturer advises that concomitant use of repotrectinib with grapefruit, grapefruit juice, or supplements that contain grapefruit should be avoided.
References (1)
- (2023) "Product Information. Augtyro (repotrectinib)." Bristol-Myers Squibb
tamsulosin food
Applies to: dutasteride / tamsulosin
ADJUST DOSING INTERVAL: Food may delay the gastrointestinal absorption of tamsulosin. The time to maximum plasma concentration (Tmax) is reached by 4 to 5 hours under fasted conditions and by 6 to 7 hours when tamsulosin is administered with food. The delay in Tmax has the desirable effect of smoothing the tamsulosin plasma concentration profile, thereby reducing fluctuation of the plasma peak and trough concentrations with multiple dosing. Food may also affect the extent of absorption of tamsulosin. It has been reported that taking tamsulosin under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak plasma concentration (Cmax) compared to fed conditions. The effects of food on the pharmacokinetics of tamsulosin are consistent regardless of whether tamsulosin is taken with a light meal or a high-fat meal.
MANAGEMENT: To ensure uniformity of absorption, tamsulosin should be administered approximately one-half hour following the same meal each day.
References (1)
- (2001) "Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.